Literature DB >> 14960658

Quantitative analysis of (-)-N-(11)C-propyl-norapomorphine in vivo binding in nonhuman primates.

Dah-Ren Hwang1, Rajesh Narendran, Yiyun Huang, Mark Slifstein, Peter S Talbot, Yasuhiko Sudo, Bart N Van Berckel, Lawrence S Kegeles, Diana Martinez, Marc Laruelle.   

Abstract

UNLABELLED: (-)-N-(11)C-propyl-norapomorphine ((11)C-NPA) is a new dopamine agonist PET radiotracer that holds potential for imaging the high-affinity states of dopamine D(2)-like receptors in the living brain. The goal of this study was to develop and evaluate analytic strategies to derive in vivo (11)C-NPA binding parameters.
METHODS: Two baboons were scanned 4 times after (11)C-NPA injections. The metabolite-corrected arterial input functions were measured. Regional brain time-activity curves were analyzed with kinetic and graphical analyses, using the arterial time-activity curve as the input function. Data were also analyzed with the simplified reference-tissue model (SRTM) and graphical analysis with reference-region input.
RESULTS: (11)C-NPA exhibited moderately fast metabolism, with 31% +/- 5% of arterial plasma concentration corresponding to the parent compound at 40 min after injection. Plasma clearance was 29 +/- 1 L/h, and plasma free fraction (f(1)) was 5% +/- 1%. For kinetic analysis, a 1-tissue compartment model (1TCM) provided a good fit to the data and more robust derivations of the tissue distribution volumes (V(T), in mL/g) than a 2-tissue compartment model (2TCM). Using 1TCM, V(T)s in the cerebellum and striatum were 3.4 +/- 0.4 and 7.5 +/- 2 mL/g, respectively, which led to estimates of striatal binding potential (BP) of 4.0 +/- 1.1 mL/g and striatal equilibrium specific-to-nonspecific partition coefficient (V(3)") of 1.2 +/- 0.2. V(T) values derived with graphical analysis were well correlated with but slightly lower than V(T) values derived with kinetic analysis. V(3)" values derived with SRTM were well correlated with but slightly higher than V(3)" values derived with kinetic analysis. Using any method, a significant difference was detected in BP and V(3)" values between the 2 animals. It was determined that 30 min of scanning data were sufficient to derive V(3)" values using kinetic, graphical (arterial input and reference-region input), and SRTM analyses.
CONCLUSION: This study indicates that (11)C-NPA is a suitable PET tracer to quantify the agonist high-affinity sites of D(2)-like receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14960658

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans.

Authors:  Jo Ann V Antenor-Dorsey; Joanne Markham; Stephen M Moerlein; Tom O Videen; Joel S Perlmutter
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

2.  (18)F-MCL-524, an (18)F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study.

Authors:  Sjoerd J Finnema; Vladimir Stepanov; Ryuji Nakao; Anna W Sromek; Tangzhi Zhang; John L Neumeyer; Susan R George; Philip Seeman; Michael G Stabin; Cathrine Jonsson; Lars Farde; Christer Halldin
Journal:  J Nucl Med       Date:  2014-05-01       Impact factor: 10.057

3.  Convenient synthesis of 18F-radiolabeled R-(-)-N-n-propyl-2-(3-fluoropropanoxy-11-hydroxynoraporphine.

Authors:  Anna W Sromek; Shaohui Zhang; Vamsidhar Akurathi; Alan B Packard; Wei Li; David Alagille; Thomas J Morley; Ronald Baldwin; Gilles Tamagnan; John L Neumeyer
Journal:  J Labelled Comp Radiopharm       Date:  2014-11-17       Impact factor: 1.921

4.  Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA: a dopamine agonist radioligand.

Authors:  Nicholas Seneca; Mette Skinbjerg; Sami S Zoghbi; Jeih-San Liow; Robert L Gladding; Jinsoo Hong; Pavitra Kannan; Edward Tuan; David R Sibley; Christer Halldin; Victor W Pike; Robert B Innis
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

5.  Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Authors:  Ariel Graff-Guerrero; Matthaeus Willeit; Nathalie Ginovart; David Mamo; Romina Mizrahi; Pablo Rusjan; Irina Vitcu; Philip Seeman; Alan A Wilson; Shitij Kapur
Journal:  Hum Brain Mapp       Date:  2008-04       Impact factor: 5.038

6.  Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PET.

Authors:  Charles M Laymon; N Scott Mason; W Gordon Frankle; Jonathan P Carney; Brian J Lopresti; Maralee Y Litschge; Chester A Mathis; James M Mountz; Rajesh Narendran
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

7.  Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies.

Authors:  Rajesh Narendran; W Gordon Frankle; N Scott Mason; Charles M Laymon; Brian J Lopresti; Julie C Price; Steve Kendro; Shivangi Vora; Maralee Litschge; James M Mountz; Chester A Mathis
Journal:  Synapse       Date:  2009-07       Impact factor: 2.562

Review 8.  Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?

Authors:  Matthieu Colom; Benjamin Vidal; Luc Zimmer
Journal:  Front Mol Neurosci       Date:  2019-10-18       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.